Add BrightSurf on Google Email

A new gene identified in the search for a therapy to treat malignant cardiac arrythmia

Researchers have discovered a novel gene therapy that can reverse conduction slowing and prevent cardiac arrhythmias by introducing the SCN10a-short gene into heart muscle cells. The treatment has shown promise in animal models and human cell studies, offering a potential solution for millions affected by arrhythmias worldwide.

SourceAmsterdam University Medical Center·JournalEuropean Heart Journal·TypeRandomized controlled/clinical trial·DateFeb 20, 2025

Biologists transform gut bacteria into tiny protein pharmacies

Researchers at Virginia Tech have developed a method to convert gut bacteria into mini protein factories that produce and release sustained flows of targeted proteins within the lower intestine. This approach eliminates a major roadblock in delivering drugs to this part of the body, offering potential treatment for chronic diseases.

SourceVirginia Tech·JournalNature·DateFeb 18, 2025

Rice-BCM research achieves gene-editing breakthrough that could improve treatment for liver disease, other disorders

The Rice University lab, in collaboration with Baylor College of Medicine, has developed a new gene-editing strategy called Repair Drive that improves the effectiveness of gene therapies in the liver. The technique enables the repair of liver cells at higher rates and equips them with a selective advantage to outcompete incorrectly edi...

SourceRice University·JournalScience Translational Medicine·TypeExperimental study·DateFeb 13, 2025

Mystery solved: New study reveals how DNA repair genes play a major role in Huntington's disease

Researchers discovered that mismatch repair genes are critical in eliciting damages to neurons vulnerable to Huntington's disease, triggering downstream pathologies and motor impairment. Targeting these genes may offer novel therapeutic approaches, including improving locomotor and gait deficits and reducing neuronal cell death.

Gene therapy may be “one shot stop” for rare bone disease

A new study adds weight to the safety and effectiveness of a gene therapy for hypophosphatasia, a rare inherited disorder that causes abnormal bone development. The treatment, AAV8-TNAP-D10, has shown promising results in mice models, with female mice achieving improvements in bone and teeth at lower doses.

SourceSanford Burnham Prebys·JournalJournal of Bone and Mineral Research·TypeExperimental study·DateFeb 3, 2025

Damon Runyon Cancer Research Foundation awards $3.2 million to innovative early-career scientists

The foundation has awarded eight recipients of the 2025 Damon Runyon-Rachleff Innovation Award, including five early-career researchers with initial grants of $400,000 over two years. The awardees aim to develop novel cancer therapies using innovative approaches such as engineered skin bacteria and small molecule-boosted drug delivery.

A battle of rafts: How molecular dynamics in CAR T cells explain their cancer-killing behavior

Researchers investigated how two CAR T cells kill cancer with distinct signaling domains. CD28.ζ-CAR molecules work quickly and efficiently, while 4-1BB.ζ-CAR molecules linger in lipid rafts for sustained collaborative killing of tumor cells. This study aims to design CAR molecules maximizing antitumor activity beyond B cell malignancies.

SourceBaylor College of Medicine·JournalScience Advances·DateJan 10, 2025

UTHealth Houston study reveals two new genes associated with variants linked to epilepsy, offering new hope for personalized therapies

Researchers at UTHealth Houston have discovered two novel genes, DYRK1A and EGFR, linked to genetic mutations causing epileptic brain lesions. This breakthrough offers a new framework for understanding epilepsy and developing targeted therapies.

SourceUniversity of Texas Health Science Center at Houston·JournalNature Communications·TypeImaging analysis·DateJan 6, 2025

Genethon presents positive initial results from a phase 1/2/3 trial of its gene therapy (GNT0004) for Duchenne Muscular Dystrophy at ASGCT Breakthroughs in Muscular Dystrophy in Chicago

Positive initial results from Genethon's gene therapy GNT0004 show stabilization of motor functions and improved dystrophin expression in patients with Duchenne Muscular Dystrophy. The therapy is expected to be launched in pivotal trial phases in Europe and the US in Q2/2025.

UAB researchers cure liver disease MASH by a one-time gene therapy

Researchers from UAB have developed a gene therapy that reverses metabolic dysfunction-associated steatohepatitis (MASH) in mice, and most obese and type 2 diabetic patients could benefit from this treatment. The therapy, based on the fibroblast growth factor 21 protein, mediates long-term reversal of liver fibrosis and MASH.

SourceUniversitat Autonoma de Barcelona·JournalMolecular Therapy·TypeExperimental study·DateNov 13, 2024

Use of “genetic scissors” carries risks

The CRISPR tool was successfully used to correct a genetic defect in cells affected by chronic granulomatous disease. However, the repair process also introduced new genetic defects, highlighting the need for caution when using CRISPR technology in clinical settings.

SourceUniversity of Zurich·JournalCommunications Biology·TypeExperimental study·DateNov 6, 2024

Single-dose gene therapy is potentially life-changing for adults with hemophilia B

A single-dose gene therapy has been shown to significantly reduce bleeding episodes in adults with hemophilia B, with an average reduction of 71% compared to standard treatment. The therapy, which enables the liver to produce clotting factor IX, has been FDA-approved for use in patients with this genetic disorder.

SourceUniversity of Pennsylvania School of Medicine·JournalNew England Journal of Medicine·DateSep 25, 2024

Genethon announces publication in Nature Communications of a next-generation gene therapy vector for muscle diseases, using AI predictive methodology to improve efficacy and safety

Genethon has developed an innovative gene therapy vector that effectively targets muscle tissue while reducing the risk of liver penetration. The new capsid design uses AI predictive methodology to improve efficacy and safety, paving the way for more effective treatments for neuromuscular diseases.

SourceAFM-Téléthon·JournalNature Communications·DateSep 12, 2024

Gene therapy effective in hereditary blindness

Researchers at Karolinska Institutet successfully used gene therapy to improve vision in 11 out of 12 patients with Bothnia dystrophy, a form of hereditary blindness. The treatment involved injecting a specially designed virus under the retina, which produced normal protein and restored visual function.

SourceKarolinska Institutet·JournalNature Communications·DateSep 10, 2024